替格瑞洛在老年急性冠脉综合征患者中的应用  

The application of ticagrelor on the elderly patients with acute coronary syndrome

作　　者：张云梅[1] 张宏[1] 赵燕[1] 庞明杰[1] 吴泳昕[1] 赵冲[1] 闻江雄[1] 周秀莉[1] 

机构地区：[1]云南省第一人民医院,云南昆明650032

出　　处：《中国老年学杂志》2014年第6期1450-1452,共3页Chinese Journal of Gerontology

基　　金：国家自然科学基金项目(No.30973751)

摘　　要：目的对比分析替格瑞洛与氯吡格雷治疗老年急性冠脉综合征患者中的临床疗效。方法选择老年(>65岁)急性冠脉综合征(ACS)患者63例,分别使用替格瑞洛和氯吡格雷,记录患者的基线资料、治疗情况,并随访3个月,比较两组患者全因死亡、再发心肌梗死、再发心绞痛及出血、药物相关的呼吸困难、室性停搏发生情况。结果相对氯吡格雷而言,替格瑞洛组再发心肌梗死、再发心绞痛低于氯吡格雷(P<0.05),而心血管死亡、严重出血两组间无差异(P>0.05)。结论对老年ACS患者,替格瑞洛可以更好地降低术后再发心梗及心绞痛的发生,且安全性好。Objective To analyze the effect of ticagrelor and clopidogrel in aged patients with acute coronary syndrome( ACS). Methods 63 cases( >65 years old) with ACS patients were given ticagrelor or clopidogrel,the all-cause mortality,reinfarction,recurrent angina pectoris and bleeding,drug related difficulty breathing,cardiac arrest occurred of the two groups were compared. Results The recurrent myocardial infarction,recurrent angina of ticagrelor group were lower than those of clopidogrel group( P<0. 05),and cardiovascular death,severe hemorrhage had no difference between the two groups. Conclusions In elderly patients with ACS,ticagrelor could reduce recurrent myocardial infarction and angina pectoris,postoperative occurrence,and the safety is good.

关 键 词：替格瑞洛 氯吡格雷 

分 类 号：R541.4[医药卫生—心血管疾病]